MPN Hub

At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, delivered a presentation on navigatin...

Hello, and welcome to our podcast. Today, Jean-Jacques Kiladjian, Consultant Hematologist from the Université Paris Cité - Hôpital Saint-Louis, Paris, France, discusses cytopenias in myelofibrosis, with a focus on clinical burden and the need for prioritized management.   This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration...

At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK, delivered a presentatio...

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition , December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Claire Harrison , Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the latest findings from the phase I/II study of nuvisertib in combination with momelotinib in patients with relapsed/refractory myelofibrosis (R/R...

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with  Jean-Jacques Kiladjian , Université Paris Cité, Paris, FR. We asked, What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?  In this interview,&nbsp...

The MPN Hub was pleased to speak with Jennifer Vaughn, The Ohio State University Comprehensive Cancer Center, Columbus, US. We asked, How might extended-release formulations of ruxolitinib benefit patients with MF? In this interview, Vaughn discusses the potential benefits of an extended-release ruxolitinib formulation for patients with myelofibrosis, noting that ruxolitinib’s short half-life nece...

The MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, What are the unmet needs in the management of myelofibrosis-related anemia? In this interview, Kiladjian explores the impact and multifactorial causes of myelofibrosis-related anemia, with particular attention to the on-target effects of JAK inhibition. He reviews current...

The MPN Hub was pleased to speak with John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, What is on the horizon for the treatment of myelofibrosis-related anemia?    In this interview, Mascarenhas explores the emerging strategies for myelofibrosis-associated anemia, with a focus on agents targeting the TGF-β superfamily members and hepcidin modulation, inc...

The MPN Hub spoke with Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. We asked about the treatment of patients with myelofibrosis-associated anemia. During this interview, Gerds discussed the burden and management of myelofibrosis-associated anemia. He explained its prevalence, prognostic importance, and multifactorial causes. Gerds also reviewed currently available therapi...

During the MPN Hub Steering Committee meeting, Francesco Passamonti, Università degli Studi di Milano, Milan, IT, chaired a discussion on novel targeted therapies for relapsed/refractory (R/R) myelofibrosis (MF), with a focus on PIM1 kinase inhibition. This discussion also featured Tiziano Barbui, Haifa Kathrin Al-Ali, Steffen Koschmieder, Jean-Jacques Kiladjian, Aaron Gerds, and Laura Michaelis.&...

During the MPN Hub Steering Committee meeting featuring John Mascarenhas, Steffen Koschmieder, Laura Michaelis, and Tiziano Barbui, Ruben Mesa discussed the use of momelotinib and luspatercept for the treatment of patients with myelofibrosis and anemia. This educational resource is independently supported by GSK and Bristol Myers Squibb. All content was developed by SES in collaboration with an ex...

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. During the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN conference, the MPN Hub hosted a symposium titled “Anemia in myelofibrosis: Sequencing therapies to...

This independent educational activity is supported by GSK.​ All content is developed independently by the faculty; the funder is allowed no influence on the content. During the European School of Haematalogy (ESH) 4th How to Diagnose and Treat CML/MPN conference, the MPN hub held a symposium on March 9, 2025, titled, Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes. Here,...

This independent educational activity was supported by GSK.​ All content was developed independently by the faculty; the funder is allowed no influence on the content. During the European School of Haematalogy (ESH) 4th How to Diagnose and Treat CML/MPN conference, the MPN Hub held a symposium on March 9, 2025, titled Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes. Here...

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. During an MPN Hub symposium presented at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN conference, MPN Hub steering committee Chair Jean-Jacques Kiladjia...

During the MPN Hub Steering Committee meeting, Ruben Mesa discussed anemia as an unmet need and the impact on quality of life and survival outcomes in patients with myelofibrosis (MF). Key points Anemia in patients with MF is a complex, multifactorial process, and can be exacerbated by treatment with some Janus kinase inhibitors, including ruxolitinib and fedratinib . Anemia is common in patients...

The MPN Hub was pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. Gerds discussed treating anemia in patients with myelofibrosis (MF). Gerds highlights the impact of anemia on survival outcomes in patients with MF, and reviews key data from the phase II ACE-536-MF-001 trial (NCT03194542) evaluating the safety and efficacy of luspatercept in patients with MF...

The MPN Hub was pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. We asked, How might luspatercept benefit patients with myelofibrosis (MF)?  Aaron Gerds opens by discussing the prevalence and issue of anemia in patients with MF, noting that almost all patients will become anemic at some point in the course of their disease. Gerds discusses luspatercep...

During the European Hematology Association (EHA) 2024 Hybrid Congress, the MPN Hub was pleased to speak with Haifa Kathrin Al-Ali, University Hospital Halle, Halle, DE. We asked, What more can be done to improve treatment for patients with polycythemia vera? Al-Ali provides an overview of how to improve treatment and outcomes for patients with polycythemia vera, opening with a discussion of the la...

The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part II - Patients with myelofibrosis (MF). Patel opens by highlighting the need for more long-term effective MF treatments and presents long-term data on the cessation of existing therapi...

The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part I — Patients with essential thrombocytopenia/polycythemia vera. In this podcast, Michaelis and Patel discuss the factors which determine whether standard of care treatment or referral...

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Laura Michaelis (Medical College of Wisconsin, Milwaukee, US) and Claire Harrison (Guy's and St Thomas' NHS Foundation Trust, London, UK). We asked, Patient follow-up in myeloproliferative neoplasms: Best practices and myths.  In this podcast, Michaelis and Harrison discuss the best practices in MPN, in par...

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Marina Kremyanskaya, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent polycythemia vera (PV)? Currently, patients with PV require frequent phlebotomy. Kremyanskaya discusses promising resu...

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Jyoti Nangalia, University of Cambridge, Cambridge, UK. We asked, Should we consider early testing and treatment for driver mutations acquired in childhood? In this podcast, Jyoti Nangalia reports results from a study using next-generation sequencing to trace acquired MPN mutations in hematopoi...

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to the Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR. We asked, When can we safely discontinue interferon alpha therapy in patients with myeloproliferative neoplasms? Results from several studies have shown that interferon alpha is able to induce high rates of co...